Skip to main content

Table 3 Grade 1 or 2 injection site reactions (incidence ≥1% in one or more treatment groups)

From: Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors

Adverse event, n (%) Study 1 Study 2a
  V930 DNA-EP V930 DNA-EP V932 Ad V932 Ad
  0.25 mg 2.5 mg 0.5 × 109vg/injection 0.5 × 1011vg/injection
  (n=6) (n=22) (n=6) (n=5)
Injection site erythema 1 (17) 14 (64) 0 3 (60)
Injection site pain 4 (67) 9 (41) 1 (17) 4 (80)
Injection site swelling 1 (17) 8 (36) 1 (17) 2 (40)
Injection site bruising 1 (17) 1(5) 0 0
Injection site papule 0 1(5) 0 0
Injection site rash 0 1(5) 0 1 (20)
  1. aSix eligible patients from Study 1 were enrolled into Study 2. Therefore, only 5 patients that had not previously participated in Study 1 were enrolled into Study 2. Overall 33 patients (not 39) were enrolled in both studies.